GSK 2798745
Alternative Names: GSK-2798745Latest Information Update: 28 Oct 2023
At a glance
- Originator GlaxoSmithKline
- Developer Biomedical Advanced Research and Development Authority; GSK
- Class Antitussives; Benzamides; Cyclohexanes; Eye disorder therapies; Heart failure therapies; Nitriles; Oxazoles; Pyrazines; Small molecules; Spiro compounds
- Mechanism of Action TRPV4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Heart failure
- Phase I/II Cough
- No development reported Diabetic macular oedema; Pulmonary oedema; Unspecified
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Diabetic-macular-oedema in Australia (PO, Tablet)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Diabetic-macular-oedema in New Zealand (PO, Tablet)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Diabetic-macular-oedema in USA (PO, Tablet)